Research Progress in the Role of Probiotics and Their Metabolites in Regulating Colorectal Cancer

被引：0

作者：

Huang, Zhoumei ^{[1
]}

Zheng, Shiqi ^{[1
]}

Sun, Jun ^{[1
]}

Yang, Jinghui ^{[1
]}

Zhou, Yingzhuo ^{[1
]}

Dong, Li ^{[1
]}

Li, Daotong ^{[1
]}

Chen, Fang ^{[1
]}

Ma, Chen ^{[1
]}

机构：

[1] National Engineering Research Center for Fruit and Vegetable Processing, College of Food Science and Nutritional Engineering, China Agricultural University, Beijing

来源：

Shipin Kexue/Food Science | 2024年 / 45卷 / 19期

关键词：

colorectal cancer; intestinal microbiota; metabolite; probiotics;

D O I：

10.7506/spkx1002-6630-20240228-153

中图分类号：

学科分类号：

摘要：

Colorectal cancer is a heterogeneous disease of the intestinal epithelium characterized by the accumulation of genetic mutations and the dysregulation of immune responses. The occurrence of colorectal cancer is the result of a combination of environmental, genetic and other factors. Among environmental factors, dietary factors are closely related to the occurrence of colorectal cancer. Dietary factors play an important role in regulating the intestinal microbiota. In addition, the composition and metabolism of the intestinal microbiome are important contributors to the development of colorectal cancer. Specific intestinal microorganisms such as Fusobacterium nucleatum have been shown to be closely correlated with the occurrence of colorectal cancer. Regulating gut microbiota has emerged as a potential means of preventing and treating colorectal cancer. In order to provide a theoretical reference for the clinical treatment of colorectal cancer, this article reviews the intervening effects of probiotics, next-generation probiotics and their metabolites on colorectal cancer, with a focus on the current status of research on the biological effects of various metabolic secretion products of probiotics, including cell-free supernatants, extracellular polysaccharides, short-chain fatty acids, bacteriocins, bacterial enzymes, bile acids and tryptophan metabolites on colorectal cancer. © 2024 Chinese Chamber of Commerce. All rights reserved.

引用

页码：364 / 375

页数：11

共 114 条

[1] OLAGUNJU A, AHMED M., Global, regional, and national burden of colorectal cancer and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019, The Lancet Gastroenterology & Hepatology, 7, 7, pp. 627-647, (2022)
[2] TORRES-MARAVILLA E, BOUCARD A S, MOHSENI A H, Et al., Role of gut microbiota and probiotics in colorectal cancer: onset and progression, Microorganisms, 9, 5, (2021)
[3] SINGH B, MITRAGOTRI S., Harnessing cells to deliver nanoparticle drugs to treat cancer, Biotechnology Advances, 42, (2020)
[4] CHRYSOSTOMOU D, ROBERTS L A, MARCHESI J R, Et al., Gut microbiota modulation of efficacy and toxicity of cancer chemotherapy and immunotherapy, Gastroenterology, 164, 2, pp. 198-213, (2023)
[5] YANG J, YU J., The association of diet, gut microbiota and colorectal cancer: what we eat may imply what we get, Protein & Cell, 9, 5, pp. 474-487, (2018)
[6] FLANAGAN L, SCHMID J, EBERT M, Et al., Fusobacterium nucleatum associates with stages of colorectal neoplasia development, colorectal cancer and disease outcome, European Journal of Clinical Microbiology & Infectious Diseases, 33, 8, pp. 1381-1390, (2014)
[7] PANDEY K R, NAIK S R, VAKIL B V., Probiotics, prebiotics and synbiotics: a review, Journal of Food Science and Technology, 52, 12, pp. 7577-7587, (2015)
[8] HUANG F, LI S J, CHEN W J, Et al., Postoperative probiotics administration attenuates gastrointestinal complications and gut microbiota dysbiosis caused by chemotherapy in colorectal cancer patients, Nutrients, 15, 2, (2023)
[9] KANG X, LIU C G, DING Y Q, Et al., Roseburia intestinalis generated butyrate boosts anti-PD-1 efficacy in colorectal cancer by activating cytotoxic CD8<sup>+</sup> T cells, Gut, 72, 11, pp. 2112-2122, (2023)
[10] 6, 1

← 1 2 3 4 5 6 7 8 9 10 →